Osmotica Pharmaceuticals plc

(NASDAQ:OSMT)

Latest On Osmotica Pharmaceuticals plc (OSMT):

Date/Time Type Description Signal Details
2021-12-14 19:31 ESTNewsOsmotica: A Different Breed Of CatN/A
2021-11-16 05:53 ESTNewsOsmotica Pharmaceuticals EPS beats by $0.04, misses on revenueN/A
2021-11-16 05:52 ESTNewsOsmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-13 06:00 ESTNewsWarning: OSMT is at high risk of performing badlyN/A
2021-10-07 16:42 ESTNewsOsmotica slips after announcing underwritten public offeringN/A
2021-10-07 16:42 ESTNewsGDS, APP, OSMT and STSA among after hours moversN/A
2021-10-07 16:42 ESTNewsOsmotica Pharma under pressure after pricing $35M share offeringN/A
2021-10-07 16:42 ESTNewsOsmotica Pharmaceuticals plunges 39% on announcing debt financing from Athyrium CapitalN/A
2021-10-01 19:25 ESTNewsOsmotica Pharmaceuticals (OSMT) Investor Presentation - SlideshowN/A
2021-08-16 22:48 ESTNewsOsmotica Pharmaceuticals reports Q2 resultsN/A
2021-08-16 22:48 ESTNewsOsmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-21 18:49 ESTNewsOsmotica surges on deal to sell legacy business and manufacturing facilityN/A
2021-07-21 18:49 ESTNewsOsmotica Pharmaceuticals, Star Equity leads healthcare gainers; Theravance Biopharma, Corbus Pharmaceuticals among major losersN/A
2021-07-21 18:34 ESTNewsOsmotica: Paring Down, Focusing On UPNEEQN/A
2021-04-01 21:18 ESTNewsOsmotica: A Tough StoryN/A
2021-03-31 06:17 ESTNewsOsmotica Pharmaceuticals EPS misses by $0.64, misses on revenueN/A
2021-03-31 06:17 ESTNewsOsmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-18 13:20 ESTAnalyst RatingThe Analyst Target Price has decreased from $8.75 to $7.75.Neutral
2021-03-16 21:40 ESTAnalyst RatingThe Analyst Target Price has increased from $8.4 to $8.75.Buy
2021-01-04 13:24 ESTNewsOsmotica Pharma plunges 27% on FDA rejection of arbaclofen in multiple sclerosisN/A
2020-12-31 08:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $9.6 to $8.4.Neutral
2020-12-30 12:05 ESTNewsOsmotica Pharmaceuticals plunges 27% on FDA response letterN/A
2020-12-30 12:04 ESTNewsOsmotica price target cut at SVB Leerink after FDA snub; retains outperform ratingN/A
2020-12-28 12:43 ESTNewsOsmotica Pharma rises 19% ahead of expected arbaclofen PDUFA tomorrowN/A
2020-12-26 11:15 ESTNewsStocks To Watch: Lemonade, AstraZeneca And FuboTV In The SpotlightN/A
2020-12-25 02:57 ESTNewsSeeking Alpha Catalyst WatchN/A
2020-12-11 10:08 ESTNewsOsmotica: In Active TransitionN/A
2020-11-26 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 20:59 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 04:53 ESTAnalyst RatingThe Analyst Target Price has increased from $9.5 to $9.6.Buy
2020-11-11 12:40 ESTEarnings EstimateAn EPS average of -$0.04 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-10 21:51 ESTNewsOsmotica Pharmaceuticals EPS beats by $0.06, beats on revenueN/A
2020-11-10 21:51 ESTNewsOsmotica Pharmaceuticals' (OSMT) CEO Brian Markison on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-08 00:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:44 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 14:11 ESTAnalyst RatingThe Analyst Target Price has increased from $9.33 to $9.5.Buy
2020-09-26 13:39 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:45 ESTFinancialsCompany financials have been released.Neutral
2020-09-03 05:39 ESTAnalyst RatingThe Analyst Target Price has increased from $9.17 to $9.33.Buy
2020-08-14 09:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 13:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-13 05:32 ESTAnalyst RatingThe Analyst Target Price has increased from $9 to $9.17.Buy
2020-08-12 22:31 ESTNewsOsmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-11 20:59 ESTNewsOsmotica Pharmaceuticals EPS misses by $0.05, misses on revenueN/A
2020-08-11 20:58 ESTNewsOsmotica Pharmaceuticals plc 2020 Q2 - Results - Earnings Call PresentationN/A
2020-08-06 21:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 01:56 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:25 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:25 ESTFinancialsCompany financials have been released.Neutral

About Osmotica Pharmaceuticals plc (OSMT):

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

OSMT Quotes by TradingView

See Advanced Chart

General

  • Name Osmotica Pharmaceuticals plc
  • Symbol OSMT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 379
  • Fiscal Year EndDecember
  • IPO Date2018-10-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://www.osmotica.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1.08
  • Price/Book (Most Recent Quarter) 1.58
  • Enterprise Value Revenue 1.65
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.21
  • Profit Margin -25%
  • Operating Margin 8%
  • Return on Assets 2%
  • Return on Equity -35%
  • Revenue 203.26 million
  • Earnings Per Share -$4.82
  • Revenue Per Share $3.51
  • Gross Profit 128.4 million
  • Quarterly Earnings Growth -12.7%
View More

Highlights

  • Market Capitalization 221.55 million
  • EBITDA 32.65 million
  • Analyst Target Price $7.75
  • Book Value Per Share $2.39
View More

Share Statistics

  • Shares Outstanding 62.59 million
  • Shares Float 20.02 million
  • % Held by Insiders 4964%
  • % Held by Institutions 42.28%
  • Shares Short 1.85 million
  • Shares Short Prior Month 2.03 million
  • Short Ratio 4.83
  • Short % of Float 12%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 2.38
  • 52 Week High $7.38
  • 52 Week Low $2.81
  • 50 Day Moving Average 4.09
  • 200 Day Moving Average 5.1
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Osmotica Pharmaceuticals plc (OSMT) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Osmotica Pharmaceuticals plc (OSMT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-10$N/A-$0.14-$0.2030%
2020-06-302020-08-11$N/A-$0.22-$0.17-31.97%
2020-03-312020-05-12$48.65 million-$0.05-$0.1973.96%
2019-12-312020-03-18$59.91 million-$0.51-$0.06-716%
2019-09-302019-11-14$65.46 million-$2.15-$0.18-1128.57%
2019-06-302019-08-08$57.53 million-$2.37-$0.04-5825%
2019-03-312019-05-09$57.13 million-$0.12-$0.11-9.09%
2018-12-312019-03-27$65.7 million-$0.07-$0.2066.35%
2018-09-302018-10-19$66.34 million-$0.10

Osmotica Pharmaceuticals plc (OSMT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Osmotica Pharmaceuticals plc (OSMT) Chart:

Osmotica Pharmaceuticals plc (OSMT) News:

Below you will find a list of latest news for Osmotica Pharmaceuticals plc (OSMT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Osmotica Pharmaceuticals plc (OSMT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Osmotica Pharmaceuticals plc (OSMT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920066364/0001104659-20-066364-index.htm
2018-06-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000018017568/0000000000-18-017568-index.htm
2018-06-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000018020245/0000000000-18-020245-index.htm
2019-12-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000019016864/0000000000-19-016864-index.htm
2020-02-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000020001248/0000000000-20-001248-index.htm
2020-08-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000020007980/0000000000-20-007980-index.htm
2020-09-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1739426/000000000020008728/0000000000-20-008728-index.htm
2018-06-20DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1739426/000091205718000269/0000912057-18-000269-index.htm
2018-07-13DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1739426/000091205718000304/0000912057-18-000304-index.htm
2018-08-22DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1739426/000091205718000349/0000912057-18-000349-index.htm
2018-09-14S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746918006231/0001047469-18-006231-index.htm
2018-10-01S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746918006503/0001047469-18-006503-index.htm
2018-10-17S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746918006732/0001047469-18-006732-index.htm
2018-10-19424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1739426/000104746918006791/0001047469-18-006791-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1739426/000104746919002635/0001047469-19-002635-index.htm
2019-06-27PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1739426/000104746919003925/0001047469-19-003925-index.htm
2019-08-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1739426/000104746919004710/0001047469-19-004710-index.htm
2019-12-20S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746919006925/0001047469-19-006925-index.htm
2020-01-06S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746920000037/0001047469-20-000037-index.htm
2020-01-10424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1739426/000104746920000180/0001047469-20-000180-index.htm
2020-01-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1739426/000104746920000640/0001047469-20-000640-index.htm
2020-04-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1739426/000104746920002440/0001047469-20-002440-index.htm
2020-07-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1739426/000104746920004086/0001047469-20-004086-index.htm
2020-07-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1739426/000104746920004108/0001047469-20-004108-index.htm
2018-09-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918057579/0001104659-18-057579-index.htm
2018-09-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918058246/0001104659-18-058246-index.htm
2018-09-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918058844/0001104659-18-058844-index.htm
2018-10-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918060750/0001104659-18-060750-index.htm
2018-10-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918060751/0001104659-18-060751-index.htm
2018-10-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918061775/0001104659-18-061775-index.htm
2018-10-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918061776/0001104659-18-061776-index.htm
2018-10-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062351/0001104659-18-062351-index.htm
2018-10-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062352/0001104659-18-062352-index.htm
2018-10-17CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062486/0001104659-18-062486-index.htm
2018-10-18FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062596/0001104659-18-062596-index.htm
2018-10-188-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1739426/000110465918062603/0001104659-18-062603-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062797/0001104659-18-062797-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062798/0001104659-18-062798-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062799/0001104659-18-062799-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062800/0001104659-18-062800-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062802/0001104659-18-062802-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062805/0001104659-18-062805-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062806/0001104659-18-062806-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062809/0001104659-18-062809-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918062811/0001104659-18-062811-index.htm
2018-10-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918063101/0001104659-18-063101-index.htm
2018-10-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918063102/0001104659-18-063102-index.htm
2018-10-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918063103/0001104659-18-063103-index.htm
2018-10-193/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918063104/0001104659-18-063104-index.htm
2018-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1739426/000110465918064411/0001104659-18-064411-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465918066965/0001104659-18-066965-index.htm
2018-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465918071202/0001104659-18-071202-index.htm
2018-12-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465918074907/0001104659-18-074907-index.htm
2019-01-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919000203/0001104659-19-000203-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003721/0001104659-19-003721-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003722/0001104659-19-003722-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003723/0001104659-19-003723-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003724/0001104659-19-003724-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003726/0001104659-19-003726-index.htm
2019-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919003727/0001104659-19-003727-index.htm
2019-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919011180/0001104659-19-011180-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919018233/0001104659-19-018233-index.htm
2019-04-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919020174/0001104659-19-020174-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919020753/0001104659-19-020753-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1739426/000110465919024092/0001104659-19-024092-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919027407/0001104659-19-027407-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919028213/0001104659-19-028213-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919030673/0001104659-19-030673-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919034190/0001104659-19-034190-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919036391/0001104659-19-036391-index.htm
2019-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919036392/0001104659-19-036392-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919036393/0001104659-19-036393-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919042186/0001104659-19-042186-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919044884/0001104659-19-044884-index.htm
2019-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919048566/0001104659-19-048566-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919051657/0001104659-19-051657-index.htm
2019-10-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465919052294/0001104659-19-052294-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465919064165/0001104659-19-064165-index.htm
2020-01-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465920001502/0001104659-20-001502-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920004321/0001104659-20-004321-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920004323/0001104659-20-004323-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920004324/0001104659-20-004324-index.htm
2020-01-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1739426/000110465920006330/0001104659-20-006330-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008835/0001104659-20-008835-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008836/0001104659-20-008836-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008837/0001104659-20-008837-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008838/0001104659-20-008838-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008839/0001104659-20-008839-index.htm
2020-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920008840/0001104659-20-008840-index.htm
2020-02-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465920012915/0001104659-20-012915-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920031919/0001104659-20-031919-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920035346/0001104659-20-035346-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920037303/0001104659-20-037303-index.htm
2020-04-08PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920044652/0001104659-20-044652-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920060178/0001104659-20-060178-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920064436/0001104659-20-064436-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920064437/0001104659-20-064437-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920064440/0001104659-20-064440-index.htm
2020-05-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920064445/0001104659-20-064445-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920065388/0001104659-20-065388-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920065389/0001104659-20-065389-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000110465920065390/0001104659-20-065390-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920066364/0001104659-20-066364-index.htm
2020-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920083089/0001104659-20-083089-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920083774/0001104659-20-083774-index.htm
2020-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920089111/0001104659-20-089111-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000110465920093327/0001104659-20-093327-index.htm
2020-09-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1739426/000110465920102621/0001104659-20-102621-index.htm
2020-09-1110-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1739426/000110465920104402/0001104659-20-104402-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1739426/000117184319000928/0001171843-19-000928-index.htm
2020-01-22SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1739426/000117184320000368/0001171843-20-000368-index.htm
2019-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1739426/000119312519030986/0001193125-19-030986-index.htm
2018-10-18CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1739426/000135445718000417/0001354457-18-000417-index.htm
2018-06-20DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1739426/000141057818000288/0001410578-18-000288-index.htm
2018-08-22DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1739426/000141057818000381/0001410578-18-000381-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837018008998/0001558370-18-008998-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1739426/000155837019002499/0001558370-19-002499-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837019004704/0001558370-19-004704-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837019007750/0001558370-19-007750-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837019011078/0001558370-19-011078-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1739426/000155837019011660/0001558370-19-011660-index.htm
2020-03-1910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1739426/000155837020002906/0001558370-20-002906-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837020006425/0001558370-20-006425-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1739426/000155837020010320/0001558370-20-010320-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175286418000001/0001752864-18-000001-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175286420000001/0001752864-20-000001-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175288018000001/0001752880-18-000001-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175380718000001/0001753807-18-000001-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175452618000001/0001754526-18-000001-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1739426/000175452620000001/0001754526-20-000001-index.htm
2018-10-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1739426/999999999518002646/9999999995-18-002646-index.htm
2020-01-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1739426/999999999520000037/9999999995-20-000037-index.htm
2020-02-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1739426/999999999520000337/9999999995-20-000337-index.htm
2018-10-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1739426/999999999718008651/9999999997-18-008651-index.htm

Osmotica Pharmaceuticals plc (OSMT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Osmotica Pharmaceuticals plc (OSMT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4964%
Institutional Ownership: 4228%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-05-20FRED G WEISSDirectorBuy38,716.00104,651.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920065389/0001104659-20-065389-index.htm
2019-01-24Andrew J. EinhornChief Financial OfficerBuy104,849.00104,849.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003723/0001104659-19-003723-index.htm
2019-01-24Tina Marie deVriesEVP, Research & DevelopmentBuy104,849.00104,849.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003726/0001104659-19-003726-index.htm
2020-01-13Avista Capital Partners III GP, L.P.10% Share HolderBuy1,250,000.005.006,250,000.0015,730,864.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920004321/0001104659-20-004321-index.htm
2020-01-13David F BurgstahlerDirectorBuy1,250,000.005.006,250,000.0015,730,864.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920004323/0001104659-20-004323-index.htm
2020-01-13Sriram VenkataramanDirectorBuy1,250,000.005.006,250,000.0015,730,864.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920004324/0001104659-20-004324-index.htm
2019-01-24Christopher KleinGeneral Counsel and SecretaryBuy104,849.00165,032.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003722/0001104659-19-003722-index.htm
2020-05-18Andrew J. EinhornChief Financial OfficerBuy71,550.00167,215.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920064440/0001104659-20-064440-index.htm
2020-05-18Tina Marie deVriesEVP, Research & DevelopmentBuy71,550.00167,259.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920064437/0001104659-20-064437-index.htm
2019-02-25BRIAN A MARKISONChief Executive OfficerBuy387,991.001,876,233.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919011180/0001104659-19-011180-index.htm
2020-05-20BRIAN A MARKISONChief Executive OfficerBuy249,787.002,126,020.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920065388/0001104659-20-065388-index.htm
2020-01-13Foundation Harsaul10% Share HolderBuy1,250,000.005.006,250,000.0022,485,297.00https://www.sec.gov/Archives/edgar/data/1739426/000175452620000001/0001754526-20-000001-index.htm
2020-01-13Ltd Altchem10% Share HolderBuy1,250,000.005.006,250,000.0022,485,297.00https://www.sec.gov/Archives/edgar/data/1739426/000175286420000001/0001752864-20-000001-index.htm
2020-05-18Christopher KleinGeneral Counsel and SecretaryBuy71,550.00227,434.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920064445/0001104659-20-064445-index.htm
2019-01-24James SchaubEVP and COOBuy104,849.00264,352.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003724/0001104659-19-003724-index.htm
2020-05-18James SchaubEVP and COOBuy73,253.00328,408.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920064436/0001104659-20-064436-index.htm
2019-01-24FRED G WEISSDirectorBuy34,403.0034,403.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003727/0001104659-19-003727-index.htm
2019-01-24GREGORY L COWANDirectorBuy34,403.0034,403.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919003721/0001104659-19-003721-index.htm
2019-06-18GREGORY L COWANDirectorBuy23,148.0057,551.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919036392/0001104659-19-036392-index.htm
2019-06-18FRED G WEISSDirectorBuy37,037.0071,440.00https://www.sec.gov/Archives/edgar/data/1739426/000110465919036391/0001104659-19-036391-index.htm
2020-05-20GREGORY L COWANDirectorBuy38,716.0090,762.00https://www.sec.gov/Archives/edgar/data/1739426/000110465920065390/0001104659-20-065390-index.htm